Synopsis
Synopsis
0
KDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-(phosphonooxy)-, Disodium Salt, (11.beta.)-
2. Schembl1650407
3. Akos025394281
4. Ft-0631728
| Molecular Weight | 484.4 g/mol |
|---|---|
| Molecular Formula | C21H27Na2O8P |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 3 |
| Exact Mass | 484.12389338 g/mol |
| Monoisotopic Mass | 484.12389338 g/mol |
| Topological Polar Surface Area | 147 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 878 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 7 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
| 1 of 2 | |
|---|---|
| Drug Name | Prednisolone sodium phosphate |
| Active Ingredient | Prednisolone sodium phosphate |
| Dosage Form | Solution/drops; Tablet, orally disintegrating; Solution |
| Route | Ophthalmic; Oral |
| Strength | eq 15mg base/5ml; eq 5mg base/5ml; eq 25mg base/5ml; eq 15mg base; eq 10mg base/5ml; eq 20mg base/5ml; eq 30mg base; eq 0.9% phosphate; eq 10mg base |
| Market Status | Prescription |
| Company | Mylan Pharms; Amneal Pharms; Wockhardt; Pharm Assoc; Mission Pharma; Hi Tech Pharma; Paddock; Vintage; Bausch And Lomb |
| 2 of 2 | |
|---|---|
| Drug Name | Prednisolone sodium phosphate |
| Active Ingredient | Prednisolone sodium phosphate |
| Dosage Form | Solution/drops; Tablet, orally disintegrating; Solution |
| Route | Ophthalmic; Oral |
| Strength | eq 15mg base/5ml; eq 5mg base/5ml; eq 25mg base/5ml; eq 15mg base; eq 10mg base/5ml; eq 20mg base/5ml; eq 30mg base; eq 0.9% phosphate; eq 10mg base |
| Market Status | Prescription |
| Company | Mylan Pharms; Amneal Pharms; Wockhardt; Pharm Assoc; Mission Pharma; Hi Tech Pharma; Paddock; Vintage; Bausch And Lomb |
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
46
PharmaCompass offers a list of Prednisolone Sodium Phosphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Prednisolone Sodium Phosphate manufacturer or Prednisolone Sodium Phosphate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Prednisolone Sodium Phosphate manufacturer or Prednisolone Sodium Phosphate supplier.
A Prozorin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Prozorin, including repackagers and relabelers. The FDA regulates Prozorin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Prozorin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Prozorin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Prozorin supplier is an individual or a company that provides Prozorin active pharmaceutical ingredient (API) or Prozorin finished formulations upon request. The Prozorin suppliers may include Prozorin API manufacturers, exporters, distributors and traders.
click here to find a list of Prozorin suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Prozorin DMF (Drug Master File) is a document detailing the whole manufacturing process of Prozorin active pharmaceutical ingredient (API) in detail. Different forms of Prozorin DMFs exist exist since differing nations have different regulations, such as Prozorin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Prozorin DMF submitted to regulatory agencies in the US is known as a USDMF. Prozorin USDMF includes data on Prozorin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Prozorin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Prozorin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Prozorin Drug Master File in Japan (Prozorin JDMF) empowers Prozorin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Prozorin JDMF during the approval evaluation for pharmaceutical products. At the time of Prozorin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Prozorin suppliers with JDMF on PharmaCompass.
A Prozorin CEP of the European Pharmacopoeia monograph is often referred to as a Prozorin Certificate of Suitability (COS). The purpose of a Prozorin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Prozorin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Prozorin to their clients by showing that a Prozorin CEP has been issued for it. The manufacturer submits a Prozorin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Prozorin CEP holder for the record. Additionally, the data presented in the Prozorin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Prozorin DMF.
A Prozorin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Prozorin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Prozorin suppliers with CEP (COS) on PharmaCompass.
A Prozorin written confirmation (Prozorin WC) is an official document issued by a regulatory agency to a Prozorin manufacturer, verifying that the manufacturing facility of a Prozorin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Prozorin APIs or Prozorin finished pharmaceutical products to another nation, regulatory agencies frequently require a Prozorin WC (written confirmation) as part of the regulatory process.
click here to find a list of Prozorin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Prozorin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Prozorin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Prozorin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Prozorin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Prozorin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Prozorin suppliers with NDC on PharmaCompass.
Prozorin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Prozorin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Prozorin GMP manufacturer or Prozorin GMP API supplier for your needs.
A Prozorin CoA (Certificate of Analysis) is a formal document that attests to Prozorin's compliance with Prozorin specifications and serves as a tool for batch-level quality control.
Prozorin CoA mostly includes findings from lab analyses of a specific batch. For each Prozorin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Prozorin may be tested according to a variety of international standards, such as European Pharmacopoeia (Prozorin EP), Prozorin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Prozorin USP).